KWA-0711

DRUG5 trials

Sponsors

Kissei Pharmaceutical Co., Ltd.

Conditions

Chronic ConstipationChronic Idiopathic Constipation

Phase 2

A Exploratory Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)

CompletedNCT01600001

Kissei Pharmaceutical Co., Ltd.Chronic Idiopathic Constipation

Target: 75Updated: 2013-10-30

A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation

CompletedNCT01937663

Kissei Pharmaceutical Co., Ltd.Chronic Constipation

Updated: 2014-11-13

A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation

CompletedNCT01938196

Kissei Pharmaceutical Co., Ltd.Chronic Constipation

Updated: 2014-11-13

Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC)

CompletedNCT02281630

Kissei Pharmaceutical Co., Ltd.Chronic Constipation

Start: 2014-10-15Updated: 2017-05-22

Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)

CompletedNCT02343978

Kissei Pharmaceutical Co., Ltd.Chronic Constipation

Start: 2014-12-26Updated: 2017-05-22

Related Papers

Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.

2018-07-2533 citations